We observed that a short ATRA treatment of neuroblastoma causes a transient SUMOylation of CYLD that reduces its deubiquitin activity, as well as activation of NF-κB signaling via ubiquitination of TRAF2/TRAF6. Here, NFKB1 is linked to neuroblastoma.